Alectinib versus crizotinib in ALK‐positive advanced non‐small cell lung cancer and comparison of next‐generation TKIs after crizotinib failure: Real‐world evidence

Abstract Background Anaplastic lymphoma kinase (ALK) fusion is a prognostic indicator for patients with non‐small cell lung cancer (NSCLC) receiving tyrosine kinase inhibitors (TKIs). The real‐world data of ALK TKIs remain a major concern. Methods Patients with ALK‐positive advanced NSCLC, who recei...

詳細記述

書誌詳細

出版年:	Cancer Medicine
主要な著者:	Yurong Wang, Shujing Shen, Peizhu Hu, Di Geng, Ruipan Zheng, Xingya Li
フォーマット:	論文
言語:	英語
出版事項:	Wiley 2022-12-01
主題:	alectinib ALK brigatinib ceritinib crizotinib PFS
オンライン･アクセス:	https://doi.org/10.1002/cam4.4834